Patient Financial Support

For Your Patients

Approximately 70% of XGEVA® patients are expected to have $0 out-of-pocket cost1*

XGEVA® patients*

XGEVA FIRST STEP Program

Help for commercially insured patients with no income eligibility requirements*

Program does not cover any other costs related to office visit or administration of XGEVA®. Other restrictions may apply.

The XGEVA FIRST STEP Program MasterCard is issued by The Bancorp Bank pursuant to license by MasterCard International and this card may not be used everywhere Debit MasterCard is accepted. No cash or ATM access. MasterCard is a registered trademark of MasterCard International Incorporated. The Bancorp Bank; Member FDIC.

* Eligibility criteria: Patients must be prescribed XGEVA® (denosumab) treatment. Patients must have private commercial insurance that covers medication costs for XGEVA® (denosumab) under a medical benefit plan. Patient may not be a participant in any federal, state or government-funded healthcare program, such as Medicare, Medicare Advantage, Medicare Part D, Medicaid, Medigap, Veterans Affairs (VA), The Department of Defense (DoD) or TRICARE.

Patients may not seek reimbursement for value received from the XGEVA FIRST STEP Program from any third-party payers, including a flexible spending account or healthcare savings accounts. If at any time patients begin receiving coverage under any federal, state, or government-funded healthcare program, patients will no longer be eligible to participate in the Amgen FIRST STEP Program and must call 1-888-65-STEP1 (1-888-657-8371) Monday through Friday, 9am-8pm EST, to stop participation. Restrictions may apply. Offer subject to change or discontinuation without notice. This is not health insurance.

The program is not valid where prohibited by law.



Tap to call Amgen Assist®
1-888-4-ASSIST (1-888-427-7478)

Indication

XGEVA® (denosumab) is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors.

XGEVA® is not indicated for the prevention of skeletal-related events in patients with multiple myeloma.

Important Safety Information

Hypocalcemia

Hypersensitivity

Drug Products with Same Active Ingredient

Osteonecrosis of the Jaw (ONJ)

Atypical Subtrochanteric and Diaphyseal Femoral Fracture

Embryo-Fetal Toxicity

Adverse Reactions

Please see Full Prescribing Information

Reference

  1. Data on file, Amgen.

Back to top

Indication and Important Safety Information

XGEVA® is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors. XGEVA® is not indicated for the prevention of skeletal-related events in patients with multiple myeloma. Read More